Lantheus Holdings Inc (NASDAQ:LNTH) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 8, 2016
Having a price of $8.23, Lantheus Holdings Inc (NASDAQ:LNTH) traded 0.98% higher on the day. With the last close up 85.26% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Lantheus Holdings Inc has recorded a 50-day average of $8.45 and a two hundred day average of $4.47. Volume of trade was down over the average, with 297,275 shares of LNTH changing hands under the typical 461,715
Zacks Investment Research has downgraded Lantheus Holdings Inc (NASDAQ:LNTH) to Hold in a statement released on 10/05/2016.
On 9/23/2016, Credit Suisse released a statement on Lantheus Holdings Inc (NASDAQ:LNTH) upped the target price from $0.00 to $8.00 that suggested a downside of -0.12%.
With a total market value of $0, Lantheus Holdings Inc has price-earnings ratio of 9.35 with a one year low of $1.76 and a one year high of $10.10 .
More About Lantheus Holdings Inc (NASDAQ:LNTH)
Lantheus Holdings, Inc. develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company's portfolio of approximately 10 commercial products is spread across a range of imaging modalities. The Company's Contrast agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging or magnetic resonance imaging (MRI), which are used by physicians to progress the clarity of the diagnostic image. Radiopharmaceuticals are radioactive pharmaceuticals used by clinicians to perform nuclear imaging procedures. The Company's imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including DEFINITY, TechneLite, Xenon Xe 133 Gas (Xenon), Cardiolite and Neurolite.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.